Availability of and challenges to resistance testing for second-line drugs, including the new and repurposed TB drugs

The Union
9/24/20, 5:00 PM
Europe/Paris GMT+2

Description

The session will report on the survey of Union members and members of Global Drug Initiative (GDI) and Global Laboratory Initiative (GLI) about the availability of drug susceptibility testing (DST), followed by a discussion of potential strategies to expand this availability.

Facilitator: Dr Alaine Umubyeyi Nyaruhirira, Management Sciences for Health, South Africa

Speakers:

Topic 1: Results of the 2020 DR-TB WG/GDI/GLI Survey, Dr Robert Horsburgh, Boston University, USA

Topic 2: Availability of and challenges to resistance testing for second-line drugs; a laboratory perspective, Dr Daniela Cirillo, Milan Supranational Reference Laboratory, Italy

Response: Availability of and challenges to resistance testing for second-line drugs; a programmatic perspective, Dr Fraser Wares, KNCV, The Netherlands

Previous registration necessary?

NO

YES
Simultaneous translation ?

NO

YES
Will it be recorded?
NO
YES

Alaine Umubyeyi Nyaruhirira

Results of the 2020 DR-TB WG/GDI/GLI Survey, Availability of and challenges to resistance testing for second-line drugs; a laboratory perspective, Response: Availability of and challenges to resistance testing for second-line drugs; a programmatic perspective

Inglês

 

Speakers

Robert Horsburgh, Daniela Cirillo, Fraser Wares

 

Link to the Event

Banner to the Event

Availability of and challenges to resistance testing for second-line drugs, including the new and repurposed TB drugs